Torrent Pharmaceuticals shares climbed 2.18% to ₹4,866.60 on Monday morning at 9:24 am, according to reports from Moneycontrol.com. This upward movement places the stock on a positive trajectory as the market begins its trading session, building on the company's recent financial performance and corporate activities.
The company's consolidated revenue for the quarter-ending March 2026 stood at ₹4,197.00 crore, representing a significant increase from ₹2,959.00 crore in the corresponding quarter of 2025, as reported by Moneycontrol. However, net profit saw a decline to ₹364.00 crore in March 2026 from ₹498.00 crore in March 2025. The diluted EPS for the March 2026 quarter was ₹11.51, compared to ₹14.71 in March 2025.
According to Moneycontrol reports, Torrent Pharmaceuticals' consolidated revenue has steadily increased from ₹8,508.04 crore in 2022 to ₹13,979.73 crore in 2026. Net profit more than doubled over this period, growing from ₹777.18 crore in 2022 to ₹2,138.18 crore in 2026. The annual diluted EPS also saw a rise from ₹45.93 in 2022 to ₹63.92 in 2026, showcasing robust financial health.
As reported by Moneycontrol, Torrent Pharmaceuticals announced a final dividend of ₹9.00 per share (180%) with an effective date of May 29, 2026, and an interim dividend of ₹29.00 per share (580%) with an effective date of February 18, 2026. In the preceding year (March 2025), the company had announced a final dividend of ₹6.00 per share (120%) effective June 20, 2025, along with an interim dividend of ₹26.00 per share (520%) effective January 31, 2025. The company also issued a bonus share in a 1:1 ratio on May 25, 2022, with an ex-bonus date of July 8, 2022.
According to Moneycontrol analysis, Torrent Pharmaceuticals is a constituent of the NIFTY NEXT 50 index, reflecting its market presence among major Indian companies. Investor sentiment toward the stock is currently bullish as of July 17, 2026, supporting the positive opening momentum observed in early trading.
